PT  - JOURNAL ARTICLE
AU  - Weng, Lu-Chen
AU  - Rämö, Joel T.
AU  - Jurgens, Sean J.
AU  - Khurshid, Shaan
AU  - Chaffin, Mark
AU  - Hall, Amelia Weber
AU  - Morrill, Valerie N.
AU  - Nauffal, Victor
AU  - Sun, Yan V.
AU  - Beer, Dominik
AU  - Lee, Simon
AU  - Nadkarni, Girish
AU  - Duong, ThuyVy
AU  - Wang, Biqi
AU  - Czuba, Tomasz
AU  - Austin, Thomas R.
AU  - Yoneda, Zachary T.
AU  - Friedman, Daniel J.
AU  - Clayton, Anne
AU  - Hyman, Matthew C.
AU  - Judy, Renae L.
AU  - Skanes, Allan C.
AU  - Orland, Kate M.
AU  - Treu, Timothy M.
AU  - Oetjens, Matthew T.
AU  - Alonso, Alvaro
AU  - Soliman, Elsayed Z.
AU  - Lin, Honghuang
AU  - Lunetta, Kathryn L.
AU  - van der Pals, Jesper
AU  - Issa, Tariq Z.
AU  - Nafissi, Navid A.
AU  - May, Heidi T.
AU  - Leong-Sit, Peter
AU  - Roselli, Carolina
AU  - Choi, Seung Hoan
AU  - ,
AU  - Khan, Habib R.
AU  - Knight, Stacey
AU  - Linnér, Richard K.
AU  - Bezzina, Connie R.
AU  - Ripatti, Samuli
AU  - Gaziano, J. Michael
AU  - Loos, Ruth
AU  - Psaty, Bruce M.
AU  - Smith, J. Gustav
AU  - Benjamin, Emelia J.
AU  - Arking, Dan E.
AU  - Rader, Daniel
AU  - Shah, Svati H.
AU  - Roden, Dan M.
AU  - Damrauer, Scott M.
AU  - Eckhardt, Lee L.
AU  - Roberts, Jason D.
AU  - Cutler, Michael J.
AU  - Shoemaker, M. Benjamin
AU  - Haggerty, Christopher M.
AU  - Cho, Kelly
AU  - Palotie, Aarno
AU  - Wilson, Peter W.F.
AU  - Ellinor, Patrick T.
AU  - Lubitz, Steven A.
TI  - Common and Rare Variant Contributions to Bradyarrhythmias from Multi-Ancestry Meta-Analyses
AID  - 10.1101/2023.09.24.23295485
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.09.24.23295485
4099  - http://medrxiv.org/content/early/2023/09/25/2023.09.24.23295485.short
4100  - http://medrxiv.org/content/early/2023/09/25/2023.09.24.23295485.full
AB  - To broaden our understanding of bradyarrhythmias and diseases of the cardiac conduction system, we performed cross-sectional multi-ancestry genome-wide association study meta-analyses in up to 1.3 million individuals for sinus node dysfunction (SND), distal conduction disease (DCD), and pacemaker implantation (PM). We evaluated the biological relevance of bradyarrhythmia loci by analyses of transcriptomes, pleiotropy, and partitioned heritability based on cardiac single cell RNA sequencing data. Finally, we performed rare variant burden testing in 460,000 whole exome sequenced individuals from two biobanks. We identified 13, 28, and 21 common variant loci for SND, DCD, and PM, respectively. Four well-known common variant arrhythmia loci (SCN5A/SCN10A, CCDC141, TBX20, and CAMK2D) were shared for SND and DCD, while other loci were more specific for either SND or DCD. Cardiomyocyte-expressed genes were strongly enriched for contributions to DCD heritability, while SND and PM were more heterogeneous. Rare variant analyses implicated LMNA for all bradyarrhythmia subtypes; SMAD6 and SCN5A for DCD; and TTN, MYBPC3, and SCN5A for PM. The genetic architectures of SND and DCD are both overlapping and distinct. Multiple genetic mechanisms involving ion channels, sarcomeric components, cellular homeostasis, and cardiac development may influence the development of bradyarrhythmias.Competing Interest StatementSAL is a full-time employee of Novartis Institutes for BioMedical Research as of July 18, 2022. Previously SAL received sponsored research support from Bristol Myers Squibb / Pfizer, Bayer AG, Boehringer Ingelheim, Fitbit, IBM, Medtronic, and Premier Inc., and consulted for Bristol Myers Squibb / Pfizer, Bayer AG, Blackstone Life Sciences, and Invitae. PTE receives sponsored research support from Bayer AG and IBM, and has consulted for Novartis, MyoKardia and Bayer AG. SMD receives research support for RenalytixAI and has consulted for Calico Labs. The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb (and Celgene Corporation & Celgene International II Sarl), Genentech Inc., Merck Sharp & Dohme LCC, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, Novartis AG, and Boehringer Ingelheim International GmbH. BMP serves on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. SMD receives research support from RenalytixAI and Novo Nordisk, outside the scope of the current research. The remaining authors report no disclosures.Funding StatementLCW is supported by NIH 1R01HL139731 and American Heart Association 18SFRN34110082. SAL is a full-time employee of Novartis Institutes for BioMedical Research as of July 18, 2022. During this work he was supported by NIH grants R01HL139731, R01HL157635 and American Heart Association 18SFRN34250007. PTE is supported by NIH 1R01HL092577 and K24HL105780, American Heart Association 18SFRN34110082, and the Foundation Leducq 14CVD01. SJJ is supported by the Junior Clinical Scientist Fellowship from the Dutch Heart foundation (Hartstichting; grant no 03-007-2022-0035). CMH is supported by NIH grants R01HL141901 and R01HL157635. NAN is supported by NIH grant T32HL007101. JTR was supported by a research fellowship from the Sigrid Juselius foundation. AP was supported by Academy of Finland Centre of Excellence in Complex Disease Genetics (grant no. 312074 and 336824). SMD is supported by IK2-CX001780. MCH is supported by Fondation Leducq (TNE FANTASY 19CV03). This publication does not represent the views of the Department of Veterans Affairs or the United States Government. JGS was supported by grants from the Swedish Heart-Lung Foundation (2022-0344, 2022-0345), the Swedish Research Council (2021-02273), the European Research Council (ERC-STG-2015-679242), Gothenburg University, Skane University Hospital, the Scania county, governmental funding of clinical research within the Swedish National Health Service, a generous donation from the Knut and Alice Wallenberg foundation to the Wallenberg Center for Molecular Medicine in Lund, and funding from the Swedish Research Council (Linnaeus grant Dnr 349-2006-237, Strategic Research Area Exodiab Dnr 2009-1039) and Swedish Foundation for Strategic Research (Dnr IRC15-0067) to the Lund University Diabetes Center. KLL was supported by NIH 1R01HL092577. EJB was supported by R01HL092577; American Heart Association AF AHA_18SFRN34110082, 75N92019D00031. SMD is supported by the US Department of Veterans Affairs Clinical Reserach and Development award IK2-CX001780. This publication does not represent the views of the Department of Veterans Affairs or the United States Government. Funding of each participating study are listed in the Supplemental Data.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa (HUS), the UK Biobank Research Ethics Committee, the Mass General Brigham Institutional Review Board, the Human Research Committee of MGB, the Intermountain Health IRB, and the MyCode Community Health Initiative gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe GWAS summary statistics are available on the Cardiovascular Disease Knowledge Portal at https://cvd.hugeamp.org/.